An interventional study of Vitamin C and Placebo in Pain, Acute, sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Recruiting at 4 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Acute Pain with a site in Canada — 8 open to participants now, 10 under way, 1 of them phase 3. Acute Pain · Canada.
Among the 61 studies in Acute Pain with a site in Canada, this one is the 10th largest by planned enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 with no phase, and was the 55th registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →8 of the 61 studies in Acute Pain with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada
Ages 6–17
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–100
York University · Sites in Canada, United Kingdom
Ages 25 wk–33 wk
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 8 · Phase 4 10
First in 2005; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 86 across 905 interventional studies indexed under Acute Pain.
Median enrollment 80 across the 54 interventional studies, 400 across the 7 observational. Of the 39 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 61 have an industry lead sponsor. The 10 most frequent:
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal is the lead sponsor of 34 studies on the registry; 16 are open to participants now.
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal has 5 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Acute Pain with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06384456University Health Network, TorontoTopical TRanexamic Acid vs. Placebo on Acute Postoperative Pain Following DRF Fixation | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies in Acute Pain with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Musculoskeletal (MSK) injuries such as sprains, strains, bruises, and fractures are among the most common reasons people visit the emergency department. These injuries often cause significant pain in the first few days, making it difficult to move, work, or sleep. Usual pain medications like ibuprofen or acetaminophen can help, but they are not safe or effective for everyone. Some people cannot take them because of heart, kidney, stomach, or liver problems. Others still experience strong pain despite treatment. Because of these limits, some patients receive opioids, which can cause side effects and carry a risk of dependence. Safer and more accessible options are needed.
Vitamin C is widely known for supporting the immune system, but research suggests it may also help reduce pain and inflammation. Studies in surgical patients have shown that vitamin C can lower pain levels, reduce the need for opioids, and support healing. These effects may be linked to its antioxidant properties and its role in tissue repair. However, no study has tested whether vitamin C can help people with recent MSK injuries treated in the emergency department.
The VICAMED study aims to answer this question. Adults arriving with an MSK injury that occurred within the past 48 hours can participate if they have at least moderate pain. Participants are randomly assigned to receive either vitamin C or a placebo. The first dose is given in the emergency department, followed by twice daily capsules for three days. Pain is measured using a simple 0-100 scale, recorded in an electronic or paper diary. A follow-up on day six helps the research team understand each participant's recovery, medication use, and overall experience.
Vitamin C is inexpensive, widely available, and very safe at the doses used in this study. If it proves effective, it could offer a simple, low risk option to help patients manage pain after an MSK injury and reduce the need for opioids in emergency care.
Background:
Acute musculoskeletal (MSK) injuries are a major cause of emergency department (ED) visits and frequently result in moderate to severe pain during the first days following presentation. First-line analgesics such as NSAIDs and acetaminophen have important contraindications and safety limitations, particularly in older adults and patients with comorbidities, underscoring the need for safe, accessible, opioid-sparing alternatives. Preclinical studies and postoperative trials suggest that vitamin C (ascorbic acid) may provide analgesic and anti-inflammatory effects through reduction of oxidative stress, protection of neural tissues, and enhanced collagen synthesis. Meta-analyses have reported reductions in postoperative opioid consumption, pain intensity, and inflammatory markers. However, no randomized controlled trial has evaluated vitamin C for acute traumatic MSK pain in the ED.
Objective:
The primary objective is to determine whether a single 900 mg oral dose of vitamin C reduces pain intensity one hour after administration compared with placebo in adults presenting with acute MSK injuries. The main secondary objective is to assess whether 900 mg of vitamin C taken twice daily for three days reduces the time-weighted sum of pain-intensity difference (SPID) over 72 hours.
Methods:
The VICAMED study is a multicentre, triple-blind, randomized, placebo-controlled trial conducted in three university-affiliated EDs in Canada. Eligible participants are adults aged ≥18 years with MSK pain ≤48 hours, triaged to ambulatory care, and reporting pain >3/10. Exclusion criteria include recent vitamin C use, active cancer, recent analgesic intake, chronic pain treatment, and contraindications such as oxalate nephropathy or interactions with cyclosporine or warfarin. Participants receive an initial 900 mg dose of vitamin C or placebo in the ED, followed by twice-daily dosing for three days. Pain intensity is measured using validated 0-100 visual analog scales through electronic or paper diaries. A structured day-six follow-up captures missing data, analgesic use, adverse events, and health-related quality of life (EQ-5D-5L). The primary analysis uses ANCOVA adjusting for site and fracture status. Secondary analyses evaluate SPID72, analgesic consumption, time to significant pain relief, time to pain-free, proportion of days with adequate relief, adverse events, and healthcare utilization.
Based on a minimal clinically important difference of 13 points on a 0-100 pain scale and prior variance estimates, 204 participants are required for the primary outcome. The sample size for SPID72 will be finalized using pilot study data currently being analyzed. The study is powered to detect clinically meaningful differences in both immediate and short-term pain trajectories.
Expected Results:
If vitamin C demonstrates analgesic efficacy in acute MSK injuries, it could represent a safe, inexpensive, widely accessible, and opioid-sparing therapeutic option for ED patients, including those unable to use NSAIDs or acetaminophen. Given its favourable safety profile and over-the-counter availability, vitamin C has strong potential for rapid clinical integration. The research team's established collaborations within national emergency medicine networks will support broad dissemination and facilitate implementation across Canadian EDs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
900 mg vitamin C taken orally twice a day
Dietary Supplement: Vitamin C
Placebo taken orally twice a day
Other: Placebo
900 mg vitamin C taken orally twice a day (one in the morning and one in the evening) for a 3-day period after ED discharge for the treatment arm.
Placebo taken orally twice a day (one in the morning and one in the evening) for a 3-day period after ED discharge for the treatment arm.
Time-weighted sum of the pain-intensity difference (SPID)
The primary outcome is the time-weighted sum of the pain-intensity difference (SPID) over the three-day treatment period on a 0-100 visual analog scale (VAS), where 0 is no pain and 100 the worst pain imaginable. The SPID accounts for both the magnitude of the pain change and its duration, producing a single value that reflects the patient's overall experience.
Time frame: Three days
Difference in pain intensity
The main secondary outcome is the difference in pain intensity, also measured on a 0-100 visual analog scale (VAS), where 0 is no pain and 100 the worst pain imaginable, between groups one hour after taking the first study drug in the ED.
Time frame: Three days
Consumption of as-needed pain medication
Participants will be asked the name and the total amount of pain medication taken during the three-day follow-up.
Time frame: Three days
Time for significant pain relief
Time for significant pain relief, reported in hours, is define in a 50% reduction in pain intensity.
Time frame: Six days
Time to pain-free
Time, reported in hours, when pain reach 0 on a 0-100 visual analog scale (VAS), where 0 is no pain and 100 the worst pain imaginable
Time frame: Six days
Percentage of days with adequate relief
To assess the proportion of days with adequate pain control, participants will answer a daily yes/no question regarding whether their pain was adequately relieved.
Time frame: Six days
New analgesic prescriptions
Numbered and of new pain medication prescription received during follow-up, even opioids.
Time frame: Three days
Adverse events
We will document during the day-six questionnaire if any of the following adverse events were experienced during the three-day period: nausea, vomiting, constipation, dizziness, drowsiness, sweating, weakness, or other adverse events.
Time frame: Three days
Quality of life improvement at six days
Health-related quality of life will be assessed using the validated EQ-5D-5L questionnaire. EuroQol - five dimensions - 5 levels. It assesses five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) across 5 levels of severity-from no problems to extreme problems-providing a 5-digit health state profile used in clinical research and economic evaluations. Common Interpretation: 11111: Perfect health (Index 1.0). 55555: Worst health (lowest possible index).
Time frame: Six days
Quantity of Healthcare visits
Participants will be asked about the number of all unscheduled or scheduled healthcare visits related to their initial pain condition during the day-6 questionnaire.
Time frame: Six days
Plan to share: Undecided — IPD could be shared upon request, upon approval by our institution.
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 39 months after the start.
Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 39 months is above that.
Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ascorbic Acid
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal